Latest news with #GSK
Daily Mail
21 hours ago
- Business
- Daily Mail
GSK strikes £370m deal with Chinese rival Jiangsu Hengrui to develop up to a dozen new medicines
GSK has struck a £370million deal with a Chinese rival to develop up to a dozen medicines, including a promising candidate for a chronic lung condition. The deal with Jiangsu Hengrui Pharmaceuticals comes as GSK focuses on growing its pipeline to negate declining revenues from top drugs and vaccines amid slowing demand and rising competition. Under the deal, GSK will gain an exclusive licence to Hengrui's HRS-9821, which is being studied as a treatment for chronic obstructive pulmonary disease. GSK shares rose 0.4 per cent, or 5.5p, to 1398p.
Mint
a day ago
- Business
- Mint
Jiangsu Hengrui Pharma stock spikes 10% to 4-year high on drug development deal with GSK – here's what the company does
Shares of Jiangsu Hengrui Pharmaceuticals Company, a Chinese pharmaceutical firm, jumped 10% to hit a 4-year high of 61-yuan, equivalent to USD 9.62 on the Shanghai Stock Exchange (SSE), after the company announced that it had agreed to license the global rights of its HRS-9821 drug and 11 other programs to GlaxoSmithKline Intellectual Property (GSK). The programs were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I), and Oncology pipeline, having been assessed for their potential best-in-class or first-in-class profiles. The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for a potential best-in-class PDE3/4 inhibitor (HRS-9821), which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, regardless of background therapy, GSK said in its filing on Monday. The British pharmaceutical giant added that HRS-9821 supports its ambition to treat patients across the widest spectrum of COPD, including those who experience continued dyspnea (shortness of breath) or are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile. The agreements also feature a pioneering, large-scale collaboration to develop up to 11 additional programs besides HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programs up to the completion of Phase I trials, including trials involving patients outside of China. GSK will have the exclusive option to further develop and commercialize each program worldwide (excluding mainland China, Hong Kong, Macau, and Taiwan) at the end of Phase I or earlier, at its discretion, and will also have program substitution rights. GSK has agreed to pay $500 million in upfront fees across the agreements, including for the license of the PDE3/4 program. The potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma could reach approximately $12 billion if all programs are optioned and all milestones are met. Additionally, Hengrui Pharma will be eligible for tiered royalties on global product net sales (excluding mainland China, Hong Kong, Macau, and Taiwan). The license to HRS-9821 remains subject to customary conditions, including regulatory clearance under the Hart-Scott-Rodino Act in the United States. Tony Wood, Chief Scientific Officer at GSK, said, 'We're delighted to announce these exciting agreements with Hengrui Pharma, which complement our already extensive pipeline. This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, while giving us the option to advance the assets with the greatest potential for patient impact.' Founded in 1970, Hengrui Pharma is a global pharmaceutical company dedicated to research, development, and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D network of 14 centers and over 5,500 professionals, Hengrui's therapeutic focus includes oncology, metabolic and cardiovascular diseases, immunological and respiratory disorders, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
Zawya
a day ago
- Business
- Zawya
UK stocks edge higher as investors assess US-EU deal
London's main stock indexes inched higher on Monday as investors assessed a trade deal between the United States and the European Union. The internationally oriented FTSE 100 rose 0.1% as of 0926 GMT, while the midcap FTSE 250 index was up 0.3%. The U.S. struck a framework trade agreement with the EU on Sunday, which imposes a 15% tariff on most EU goods and requires the bloc to invest around $600 billion in the U.S. British Prime Minister Keir Starmer will meet U.S. President Donald Trump in Scotland on Monday for talks ranging from their recent bilateral trade deal to the worsening hunger crisis in Gaza. Automobiles and parts stocks led the sectoral gains, up 1.1%. The real estate sector advanced 0.8%, with Rightmove up 2.3% and Segro rising 1.1%. On the flip side, industrial miners led the sectoral declines, down 0.9%, tracking lower metal prices. Miners Glencore lost 1.4% and Rio Tinto fell 1%. In company news, GSK rose 1.3% after the drugmaker and China's Jiangsu Hengrui Pharmaceuticals agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition. Ocean Wilsons Holdings lost 10.6%, top loser on the mid-cap FTSE 250 index, after the investment holding company and Hansa Investment agreed to an all-share merger to create a diversified investment firm with more than 900 million pounds ($1.21 billion) in net assets. Meanwhile, the Bank of England is expected to slow the pace soon at which it shrinks its 558 billion-pound ($754 billion) holdings of government bonds, with economists hoping for some clarity next week on the central bank's longer-term goals for the stockpile. Traders are currently pricing in an 86.5% chance of a 25 basis point BoE cut on August 7, according to data compiled by LSEG. (Reporting by Sukriti Gupta in Bengaluru; Editing by Shinjini Ganguli)
Reuters
a day ago
- Business
- Reuters
UK stocks edge higher as investors assess US-EU deal
July 28 (Reuters) - London's main stock indexes inched higher on Monday as investors assessed a trade deal between the United States and the European Union. The internationally oriented FTSE 100 (.FTSE), opens new tab rose 0.1% as of 0926 GMT, while the midcap FTSE 250 index (.FTMC), opens new tab was up 0.3%. The U.S. struck a framework trade agreement with the EU on Sunday, which imposes a 15% tariff on most EU goods and requires the bloc to invest around $600 billion in the U.S. British Prime Minister Keir Starmer will meet U.S. President Donald Trump in Scotland on Monday for talks ranging from their recent bilateral trade deal to the worsening hunger crisis in Gaza. Automobiles and parts (.FTNMX401010), opens new tab stocks led the sectoral gains, up 1.1%. The real estate sector (.FTUB3510), opens new tab advanced 0.8%, with Rightmove (RMV.L), opens new tab up 2.3% and Segro (SGRO.L), opens new tab rising 1.1%. On the flip side, industrial miners (.FTNMX551020), opens new tab led the sectoral declines, down 0.9%, tracking lower metal prices. Miners Glencore (GLEN.L), opens new tab lost 1.4% and Rio Tinto (RIO.L), opens new tab fell 1%. In company news, GSK (GSK.L), opens new tab rose 1.3% after the drugmaker and China's Jiangsu Hengrui Pharmaceuticals ( opens new tab agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition. Ocean Wilsons Holdings (OCN.L), opens new tab lost 10.6%, top loser on the mid-cap FTSE 250 index, after the investment holding company and Hansa Investment (HAN.L), opens new tab agreed to an all-share merger to create a diversified investment firm with more than 900 million pounds ($1.21 billion) in net assets. Meanwhile, the Bank of England is expected to slow the pace soon at which it shrinks its 558 billion-pound ($754 billion) holdings of government bonds, with economists hoping for some clarity next week on the central bank's longer-term goals for the stockpile. Traders are currently pricing in an 86.5% chance of a 25 basis point BoE cut on August 7, according to data compiled by LSEG.
Yahoo
a day ago
- Business
- Yahoo
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas, including respiratory, immunology and inflammation, and oncology. The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031. GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme. The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions. A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD). HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics. In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio. Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally." Beyond HRS-9821, the collaboration includes up to 11 additional programmes. Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan. This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities. The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US. In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. "Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
